Clinical Trials Logo

Bietti's Crystalline Dystrophy clinical trials

View clinical trials related to Bietti's Crystalline Dystrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06302608 Active, not recruiting - Clinical trials for Bietti's Crystalline Dystrophy

Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy

Start date: February 8, 2023
Phase: Early Phase 1
Study type: Interventional

Evaluate the safety and tolerability of NGGT001 subretinal injection for the treatment of crystalline retinal degeneration (BCD)

NCT ID: NCT05832684 Recruiting - Clinical trials for Bietti's Crystalline Dystrophy

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Start date: February 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.

NCT ID: NCT05714904 Recruiting - Clinical trials for Bietti's Crystalline Dystrophy

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Start date: September 23, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of an adeno-associated virus vector expressing CYP4V2 in patients with Bietti's crystalline dystrophy (BCD).

NCT ID: NCT04722107 Recruiting - Clinical trials for Bietti's Crystalline Dystrophy

Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)

Start date: April 21, 2021
Phase: Early Phase 1
Study type: Interventional

Primary Objectives: To evaluate the safety of rAAV2/8-hCYP4V2 gene replacement therapy drug administered as a single subretinal injection in patients with Bietti's Crystalline Dystrophy (BCD). Secondary Objectives: To preliminarily explore the clinical effectiveness of rAAV2/8-hCYP4V2 gene replacement therapy drugs.